AlphAIAlphAI — Financial news for AI agents
investing.comSEP 113 min read$VNDA

Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage

Vanda Pharmaceuticals (VNDA) outlined its growth plans at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, targeting $750M in psychiatry revenue by 2030. The company expects BYSANTI, approved for bipolar disorder and schizophrenia, to be a key catalyst with a favorable pricing structure. VNDA also highlighted its pipeline, including NEREUS for motion sickness and potential GLP-1-related nausea and vomiting. Fanapt, a current growth driver, has a 30% year-over-year growth rate. The

Original reporting
investing.com
Published Sep 11, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 5:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefSector analysis
Primary signal
$VNDA
Bullish
medium confidence
Mentioned
$VNDA
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$VNDABullishMed
01

Why it matters

The company’s guidance on revenue targets and pipeline timelines provides new data points for valuation models.

02

Market read

Fresh corporate guidance for a micro‑cap biotech, introducing new catalysts that may affect trading decisions.

03

What to watch

Potential reimbursement challenges and competition in the antipsychotic market could limit upside.

Relevance 6/10Novelty 6/10Timing: post‑conference Friday

Background

Vanda Pharmaceuticals used the Cantor Healthcare Conference to outline its growth strategy centered on psychiatry products.

Company-level read

Ticker impact

$VNDABullishMedium confidence
Context

Vanda Pharmaceuticals disclosed new pipeline timelines, BYSANTI launch expectations, and revenue targets at its Cantor conference.

Expected impact

Potential upside if BYSANTI launch proceeds as planned and pipeline data meet expectations.

Evidence & confidence

New product launch and pipeline milestones are primary news for a micro‑cap biotech, offering actionable insight for traders.

Market effects

Sector

Highlights continued investment in psychiatry therapeutics within the biotech sector.

Regional

U.S. biotech investors may re‑evaluate exposure to psychiatry pipelines.

Global

Limited to U.S. and global biotech investors tracking psychiatric drug development.

Counterpoint

What could challenge this read

If BYSANTI launch delays persist, the stock could face pressure despite the announced roadmap.

Key entities

  • Executive
    Kevin Moran

    Senior Vice President and CFO who presented the growth plan.

Read at source← All news

Related articles

SEP 29
$VNDAHighAI 9/10

Why is Vanda Pharmaceuticals stock surging today?

Vanda Pharmaceuticals (VNDA) stock rose 12% in after-hours trading to $5.63 after reporting positive phase III results for its Hetlioz treatment in delayed sleep-wake phase disorder. The trial met its primary endpoint, and the company plans to discuss the data with the FDA. If approved, Hetlioz would be the first FDA-approved medicine for this condition.

investing.com2 min
SEP 11
$VNDAMedAI 8/10

VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth

Vanda Pharmaceuticals Inc. [VNDA] launched two new drugs, NEREUS and BYSANTI. BYSANTI's launch and a switch strategy from Fanapt are expected to drive near-term revenue. The company aims for $750 million in psychiatry revenue by 2030, supported by phase III readouts and product diversification, according to its 12th Annual Cantor Fitzgerald Global Healthcare Conference.

tradingview.com1 min
AUG 24
$VNDAMedAI 8/10

Vanda receives EU orphan designation for imsidolimab GPP treatment

Vanda Pharmaceuticals (VNDA) received EU orphan designation for imsidolimab, a potential treatment for generalized pustular psoriasis, following a positive opinion from the EMA. The designation, the first for a GPP treatment in the EU, may provide regulatory and market benefits. The company's Biologics License Application for imsidolimab is under FDA review with a target action date of December 12, 2026.

grafa.com1 min
AUG 24
$VNDAMed

Vanda Wins First EU Orphan Designation For Imsidolimab In Generalized Pustular Psoriasis; Stock Up

Vanda Pharmaceuticals (VNDA) received EU Orphan Drug Designation for Imsidolimab to treat generalized pustular psoriasis. The designation, granted by the European Commission, follows a positive opinion from the EMA. Imsidolimab targets the IL-36 signaling pathway. VNDA's stock rose 6.06% in pre-market trading. The FDA is reviewing the drug's BLA with a target action date of December 12, 2026.

rttnews.com2 min